image
Healthcare - Biotechnology - NASDAQ - US
$ 19.28
-2.84 %
$ 2.42 B
Market Cap
-10.82
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one APLS stock under the worst case scenario is HIDDEN Compared to the current market price of 19.3 USD, Apellis Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one APLS stock under the base case scenario is HIDDEN Compared to the current market price of 19.3 USD, Apellis Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one APLS stock under the best case scenario is HIDDEN Compared to the current market price of 19.3 USD, Apellis Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart APLS

image
$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
781 M REVENUE
97.02%
-165 M OPERATING INCOME
68.10%
-198 M NET INCOME
62.57%
-87.9 M OPERATING CASH FLOW
85.23%
-403 K INVESTING CASH FLOW
40.21%
149 M FINANCING CASH FLOW
-62.17%
167 M REVENUE
-21.52%
-83.3 M OPERATING INCOME
-218.48%
-92.2 M NET INCOME
-153.69%
-53.4 M OPERATING CASH FLOW
-275.88%
-8 K INVESTING CASH FLOW
60.00%
274 K FINANCING CASH FLOW
106.85%
Balance Sheet Apellis Pharmaceuticals, Inc.
image
Current Assets 789 M
Cash & Short-Term Investments 411 M
Receivables 272 M
Other Current Assets 106 M
Non-Current Assets 96.1 M
Long-Term Investments 0
PP&E 19 M
Other Non-Current Assets 77.1 M
46.47 %30.70 %11.97 %8.71 %Total Assets$885.1m
Current Liabilities 186 M
Accounts Payable 38.6 M
Short-Term Debt 6.75 M
Other Current Liabilities 140 M
Non-Current Liabilities 471 M
Long-Term Debt 463 M
Other Non-Current Liabilities 7.97 M
5.88 %21.35 %70.53 %Total Liabilities$656.5m
EFFICIENCY
Earnings Waterfall Apellis Pharmaceuticals, Inc.
image
Revenue 781 M
Cost Of Revenue 118 M
Gross Profit 664 M
Operating Expenses 829 M
Operating Income -165 M
Other Expenses 32.9 M
Net Income -198 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)781m(118m)664m(829m)(165m)(33m)(198m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.93% GROSS MARGIN
84.93%
-21.11% OPERATING MARGIN
-21.11%
-25.32% NET MARGIN
-25.32%
-86.58% ROE
-86.58%
-22.36% ROA
-22.36%
-23.50% ROIC
-23.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Apellis Pharmaceuticals, Inc.
image
00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -198 M
Depreciation & Amortization 1.8 M
Capital Expenditures -403 K
Stock-Based Compensation 114 M
Change in Working Capital -18.4 M
Others 12.4 M
Free Cash Flow -88.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Apellis Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for APLS of $71.9 , with forecasts ranging from a low of $39 to a high of $96 .
APLS Lowest Price Target Wall Street Target
39 USD 102.28%
APLS Average Price Target Wall Street Target
71.9 USD 272.80%
APLS Highest Price Target Wall Street Target
96 USD 397.93%
Price
Max Price Target
Min Price Target
Average Price Target
100100909080807070606050504040303020201010Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Apellis Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
3.4 M USD 2
3-6 MONTHS
374 K USD 10
6-9 MONTHS
2.71 M USD 11
9-12 MONTHS
1.37 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, California. These data further demonstrate the robust efficacy and well-documented safety profile of SYFOVRE ® (pegcetacoplan injection) for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). globenewswire.com - 1 week ago
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects. zacks.com - 3 weeks ago
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) STOCKHOLM , July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the European Union for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). "We are pleased to continue our ongoing partnership with Apellis and share their strong belief in Aspaveli/EMPAVELI's potential to deliver significant long-term growth," said Guido Oelkers, Chief Executive Officer at Sobi. prnewswire.com - 3 weeks ago
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300 million in exchange for 90% of Apellis' future ex-U.S. royalties for Aspaveli® (systemic pegcetacoplan). Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI®. globenewswire.com - 3 weeks ago
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress. globenewswire.com - 1 month ago
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. globenewswire.com - 1 month ago
Apellis Pharmaceuticals: Have Some Patience Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing GA progression and saw a 122% YoY sales increase in 2024, despite initial rollout issues. EMPAVELI® offers moderate sales and is in trials for additional indications, promising incremental cash flows and contributing to EBITDA positivity by 2026. seekingalpha.com - 2 months ago
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates. zacks.com - 2 months ago
Why Apellis Pharmaceuticals Wilted on Wednesday A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (^GSPC 0.43%) closed in the black with a 0.4% gain. fool.com - 2 months ago
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and Chief Executive Officer Tim Sullivan – Chief Financial Officer David Acheson – Executive Vice President-Commercial Caroline Baumal – Chief Medical Officer Conference Call Participants Jon Miller – Evercore Tazeen Ahmad – Bank of America Securities Anupam Rama – JPM Steve Seedhouse – Cantor Colleen Kusy – Baird Eliana Merle – UBS Annabel Samimy – Stifel Biren Amin – Piper Sandler Yigal Nochomovitz – Citigroup Douglas Tsao – H.C. Wainwright Lachlan Hanbury-Brown – William Blair Ryan Deschner – Raymond James Judah Frommer – Morgan Stanley Greg Harrison – Scotiabank Graig Suvannavejh – Mizuho Securities Lisa Walter – RBC Operator Hello, everyone. seekingalpha.com - 2 months ago
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 2 months ago
8. Profile Summary

Apellis Pharmaceuticals, Inc. APLS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.42 B
Dividend Yield 0.00%
Description Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Contact 100 Fifth Avenue, Waltham, MA, 02451 https://www.apellis.com
IPO Date Nov. 9, 2017
Employees 705
Officers Prof. Peter Hillmen M.D., Ph.D. Head of Hematology Engagement & Member of PNH Scientific Advisory Board Mr. David O. Watson Esq., J.D. General Counsel & Secretary Dr. Caroline R. Baumal M.D. Chief Medical Officer Dr. Pascal Deschatelets Ph.D. Co-Founder & Chief Scientific Officer Ms. Meredith Kaya Senior Vice President, Investor Relations & Strategic Finance Ms. Victoria L. Brown Senior Vice President Mr. Alec Machiels J.D., MBA Co-Founder & Director Mr. James G. Chopas CPA Vice President, Corporate Controller & Chief Accounting Officer Dr. Cedric Francois M.D., Ph.D. Co-Founder, President, Chief Executive Officer & Director Mr. Timothy E. Sullivan Chief Financial Officer & Treasurer